Esperion Therapeutics, Inc. $ESPR is AIGH Capital Management LLC's 10th Largest Position

Key Points

• Archimed agreed to acquire Esperion in a deal valuing the company at about ~$1.1 billion, offering $3.16 per share in cash plus the right to participate in up to $100 million of contingent milestone payments, a primary catalyst for the stock.
• AIGH Capital Management boosted its stake by 33.3% to 4,000,000 shares, making Esperion its 10th-largest holding and representing roughly a 1.67% ownership position valued at about $14.8 million.
• Multiple shareholder‑rights law firms have opened investigations alleging shareholders may not be receiving a fair price, which could lead to litigation, a negotiated price change, or delays to the transaction.

AIGH Capital Management LLC lifted its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,000,000 shares of the biopharmaceutical company's stock after buying an additional 1,000,000 shares during the period. Esperion Therapeutics comprises 3.6% of AIGH Capital Management LLC's investment portfolio, making the stock its 10th biggest holding. AIGH Capital Management LLC owned approximately 1.67% of Esperion Therapeutics worth $14,800,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. DHJJ Financial Advisors Ltd. raised its stake in shares of Esperion Therapeutics by 209.2% during the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 6,380 shares in the last quarter. KFG Wealth Management LLC purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth approximately $37,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Esperion Therapeutics by 49.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company's stock worth $43,000 after buying an additional 3,822 shares in the last quarter. Finally, R Squared Ltd purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $33,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ESPR. HC Wainwright reissued a "neutral" rating and set a $3.16 target price on shares of Esperion Therapeutics in a research note on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, March 14th. Citizens Jmp raised their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the company a "market outperform" rating in a research note on Friday, March 13th. Finally, Needham & Company LLC raised their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $5.54.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR opened at $3.11 on Friday. Esperion Therapeutics, Inc. has a 1-year low of $0.69 and a 1-year high of $4.18. The business has a 50-day moving average of $2.55 and a 200-day moving average of $3.07. The company has a market capitalization of $800.53 million, a price-to-earnings ratio of -18.29, a PEG ratio of 1.62 and a beta of 1.17.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $168.45 million during the quarter, compared to the consensus estimate of $165.12 million. Research analysts expect that Esperion Therapeutics, Inc. will post 0.05 EPS for the current fiscal year.

Key Headlines Impacting Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Archimed agreed to acquire Esperion in a deal valuing the company at as much as ~$1.1 billion; shareholders are to receive $3.16 per share in cash plus the right to participate in up to $100 million of contingent milestone payments — the bid is the primary catalyst lifting the stock. Article Title Article Title
• Neutral Sentiment: HC Wainwright reaffirmed a "neutral" rating and set a $3.16 price target — the PT matches the deal cash price, effectively signaling analyst alignment with the offer price but leaving little upside under the transaction. Article Title
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement for "news pending," consistent with a material corporate event; halts are routine but can compress post‑halt volatility. (Internal trading halt notice)
• Neutral Sentiment: Unusual options activity: roughly 7,568 calls were bought — about a 212% increase versus typical daily call volume — indicating speculative or arbitrage positioning around the deal. This can amplify intraday moves but doesn’t change deal economics. (Options flow report)
• Negative Sentiment: Multiple shareholder‑rights law firms (Monteverde & Associates/M&A Class Action Firm, Ademi LLP, and Halper Sadeh LLC) have opened investigations alleging Esperion shareholders may not be receiving a fair price, which could lead to litigation, a negotiated price revision, or delays to closing. Article Title Article Title Article Title

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.